Received Feb 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | XN575 | — |
received another dose of Boostrix by accident to patient 32 weeks pregnant; administered a 1st dose of Boostrix to a pregnant; Two doses of Boostrix during pregnancy.; This non-serious prospective pregnancy case was reported by a other health professional via call center representative and described the occurrence of vaccine exposure during pregnancy in a 19-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number XN575, expiry date 22-MAR-2027) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) (batch number MC7HK, expiry date 25-JAN-2027) for prophylaxis. On 15-JAN-2025, the patient received the 2nd dose of Boostrix. On 02-JAN-2025, the patient received the 1st dose of Boostrix. On 15-JAN-2025, an unknown time after receiving Boostrix and not applicable after receiving Boostrix, the patient experienced extra dose administered (Verbatim: Two doses of Boostrix during pregnancy.). On an unknown date, the patient experienced vaccine exposure during pregnancy (Verbatim: received another dose of Boostrix by accident to patient 32 weeks pregnant) and vaccine exposure during pregnancy (Verbatim: administered a 1st dose of Boostrix to a pregnant). The outcome of the vaccine exposure during pregnancy, vaccine exposure during pregnancy and extra dose administered were unknown. Pregnancy exposure: Pregnancy Exposure (Boostrix): To mother in third trimester Pregnancy Exposure (Boostrix): To mother in third trimester Pregnancy Outcome: Pregnancy was ongoing This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 15-JAN-2025 The reporter informed that they administered a dose of Boostrix to a pregnant patient and same patient received another dose of Boostrix by accident, which led vaccine exposure during pregnancy and extra dose administered. Reporter mentioned patient was 32 weeks pregnant when she received the 2nd dose of Boostrix. The reporter consented to follow up